Login to Your Account



Deals And M&A NEWS

LONDON – Novartis AG and Glaxosmithkline plc are exchanging assets in a three-way, "supercomplex" deal that will see Novartis paying $16 billion for GSK's marketed oncology portfolio, while GSK acquires Novartis' vaccines arm for $5.25 billion.

'TWIST' AND DOUBT
As Tuesday wore on, skepticism gave way regarding success for the hostile try by Valeant Pharmaceuticals International Inc., with help from the hedge fund Pershing Square Capital Management L.P., to take over Allergan Inc. in a deal valued at about $45 billion. But the merger is by no means a deal.
'NICE AND EASY' TERMS

TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.

More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: